140 related articles for article (PubMed ID: 21455329)
1. Does deep sedation impact the results of 48 hours catheterless pH testing?
Korrapati V; Babich JP; Balani A; Grendell JH; Kongara KR
World J Gastroenterol; 2011 Mar; 17(10):1304-7. PubMed ID: 21455329
[TBL] [Abstract][Full Text] [Related]
2. Bravo (wireless) ambulatory esophageal pH monitoring: how do day 1 and day 2 results compare?
Bechtold ML; Holly JS; Thaler K; Marshall JB
World J Gastroenterol; 2007 Aug; 13(30):4091-5. PubMed ID: 17696227
[TBL] [Abstract][Full Text] [Related]
3. 24 Versus 48-hour bravo pH monitoring.
Chander B; Hanley-Williams N; Deng Y; Sheth A
J Clin Gastroenterol; 2012 Mar; 46(3):197-200. PubMed ID: 21959323
[TBL] [Abstract][Full Text] [Related]
4. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
Schey R; Alla SP; Midani D; Parkman HP
Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
[TBL] [Abstract][Full Text] [Related]
5. Esophagogastroduodenoscopy with conscious sedation does not interfere with catheter-based 24-h pH monitoring.
Tsou YK; Lien JM; Chen CK; Lin CH; Chen HY; Lee MS
World J Gastroenterol; 2013 Mar; 19(11):1805-10. PubMed ID: 23555169
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of wireless pH-monitoring of gastro-esophageal reflux in children before and after proton pump inhibitors.
Boström M; Thorsson O; Toth E; Agardh D
BMC Gastroenterol; 2014 Dec; 14():3. PubMed ID: 25539736
[TBL] [Abstract][Full Text] [Related]
7. Esophageal pH monitoring with the BRAVO capsule: experience in a single tertiary medical center.
Cabrera J; Davis M; Horn D; Pfefferkorn M; Croffie JM
J Pediatr Gastroenterol Nutr; 2011 Oct; 53(4):404-8. PubMed ID: 21519281
[TBL] [Abstract][Full Text] [Related]
8. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
9. [The Additional Role of Symptom-Reflux Association Analysis of Diagnosis of Gastroesophageal Reflux Disease Using Bravo Capsule pH Test].
Jung K; Park MI; Park SJ; Moon W; Kim SE; Kim JH
Korean J Gastroenterol; 2017 Oct; 70(4):169-175. PubMed ID: 29060954
[TBL] [Abstract][Full Text] [Related]
10. Comparison of data obtained from sedated versus unsedated wireless telemetry capsule placement: does sedation affect the results of ambulatory 48-hour pH testing?
Belafsky PC; Godin DA; Garcia JC; Rahim N
Laryngoscope; 2005 Jun; 115(6):1109-13. PubMed ID: 15933532
[TBL] [Abstract][Full Text] [Related]
11. Continuous 48-Hour Wireless Esophageal pH Monitoring in Children: Comparison Between Days 1 and 2.
Ravi A; Gunasekaran T; Berman J
J Pediatr Gastroenterol Nutr; 2016 Jan; 62(1):87-9. PubMed ID: 26196198
[TBL] [Abstract][Full Text] [Related]
12. Day-to-day variability in acid reflux patterns using the BRAVO pH monitoring system.
Ahlawat SK; Novak DJ; Williams DC; Maher KA; Barton F; Benjamin SB
J Clin Gastroenterol; 2006 Jan; 40(1):20-4. PubMed ID: 16340628
[TBL] [Abstract][Full Text] [Related]
13. Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy.
Hirano I; Zhang Q; Pandolfino JE; Kahrilas PJ
Clin Gastroenterol Hepatol; 2005 Nov; 3(11):1083-8. PubMed ID: 16271338
[TBL] [Abstract][Full Text] [Related]
14. 48-Hour pH monitoring increases the risk of false positive studies when the capsule is prematurely passed.
Iqbal A; Lee YK; Vitamvas M; Oleynikov D
J Gastrointest Surg; 2007 May; 11(5):638-41. PubMed ID: 17468923
[TBL] [Abstract][Full Text] [Related]
15. Oesophageal pH monitoring using the Bravo catheter-free radio capsule.
Gillies RS; Stratford JM; Booth MI; Dehn TC
Eur J Gastroenterol Hepatol; 2007 Jan; 19(1):57-63. PubMed ID: 17206078
[TBL] [Abstract][Full Text] [Related]
16. [Successful esophageal pH monitoring with Bravo capsule in patients with gastroesophageal reflux disease].
Valdovinos Díaz MA; Remes Troche JM; Ruiz Aguilar JC; Schmulson MJ; Valdovinos-Andraca F
Rev Gastroenterol Mex; 2004; 69(2):62-8. PubMed ID: 15757153
[TBL] [Abstract][Full Text] [Related]
17. Impact of prolonged 48-h wireless capsule esophageal pH monitoring on diagnosis of gastroesophageal reflux disease and evaluation of the relationship between symptoms and reflux episodes.
Domingues GR; Moraes-Filho JP; Domingues AG
Arq Gastroenterol; 2011; 48(1):24-9. PubMed ID: 21537538
[TBL] [Abstract][Full Text] [Related]
18. 24-h multichannel intraluminal impedance-pH monitoring may be an inadequate test for detecting gastroesophageal reflux in patients with mixed typical and atypical symptoms.
Han MS; Lada MJ; Nieman DR; Tschoner A; Peyre CG; Jones CE; Watson TJ; Peters JH
Surg Endosc; 2015 Jul; 29(7):1700-8. PubMed ID: 25398192
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Gastroesophageal Reflux Disease in Children on the Autism Spectrum: A Study Evaluating the Tolerance and Utility of the BRAVO Wireless pH Monitoring.
Rodriguez L; Morley-Fletcher A; Winter H; Timothy B
J Pediatr Gastroenterol Nutr; 2022 Oct; 75(4):450-454. PubMed ID: 35830732
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and clinical utility of the Bravo pH capsule in children.
Lacy BE; Edwards S; Paquette L; Weiss J; Kelley ML; Ornvold K
J Clin Gastroenterol; 2009 Jul; 43(6):514-9. PubMed ID: 19349903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
